How times a day do you take this medicine?
What is Ciprofloxacin ACS Dobfar?
Ciprofloxacin ACS Dobfar is an antibiotic in a group of drugs called fluoroquinolones (flor-o-KWIN-o-lones). Ciprofloxacin ACS Dobfar fights bacteria in the body.
Ciprofloxacin ACS Dobfar is used to treat different types of bacterial infections. Ciprofloxacin ACS Dobfar is also used to treat people who have been exposed to anthrax.
Ciprofloxacin ACS Dobfar may also be used for purposes not listed in this medication guide.
Ciprofloxacin ACS Dobfar indications
Ciprofloxacin ACS Dobfar Injection, USP is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. Please see for specific recommendations.
Urinary Tract Infections caused by Escherichia coli (including cases with secondary bacteremia), Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri (diversus), Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or vancomycin-susceptible Enterococcus faecalis.
Lower Respiratory Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae*. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis.
*Ciprofloxacin ACS Dobfar is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae.
Nosocomial Pneumonia caused by Haemophilus influenzae or Klebsiella pneumoniae.
Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes.
Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa.
Complicated Intra-Abdominal Infections (used in conjunction with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis.
Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis.
Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis.
Empirical Therapy for Febrile Neutropenic Patients in combination with piperacillin sodium.
Pediatric Patients (1 to 17 years of age)
Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli.
NOTE: Although effective in clinical trials, Ciprofloxacin ACS Dobfar is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin ACS Dobfar, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals.
Adult and Pediatric Patients
Inhalational Anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
Ciprofloxacin ACS Dobfar serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.6 Supportive clinical information for Ciprofloxacin ACS Dobfar for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001.
If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to Ciprofloxacin ACS Dobfar. Therapy with Ciprofloxacin ACS Dobfar Injection, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.
As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Ciprofloxacin ACS Dobfar. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin ACS Dobfar Injection, USP and other antibacterial drugs, Ciprofloxacin ACS Dobfar Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Ciprofloxacin ACS Dobfar?
Use Ciprofloxacin ACS Dobfar as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Ciprofloxacin ACS Dobfar may be used around the eye or in the eye. To use Ciprofloxacin ACS Dobfar in the eye, first, wash your hands. Using your index finger, pull the lower eyelid away from your eye to form a pouch. Squeeze a thin strip of ointment into the pouch. After using Ciprofloxacin ACS Dobfar, gently close your eyes for 1 to 2 minutes. Wash your hands to remove any medicine that may be on them. Wipe the applicator tip with a clean, dry tissue.
- To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.
- Do not wear contact lenses while you are using Ciprofloxacin ACS Dobfar. Take care of your contact lenses as directed by the manufacturer. Check with your doctor before you use them.
- To clear up your infection completely, take/use Ciprofloxacin ACS Dobfar for the full course of treatment. Keep taking/using it even if you feel better in a few days.
- If you miss a dose of Ciprofloxacin ACS Dobfar, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Ciprofloxacin ACS Dobfar.
Uses of Ciprofloxacin ACS Dobfar in details
Ciprofloxacin ACS Dobfar is used to treat wide range of bacterial infections including lung or respiratory tract infections, eye infection, bladder and kidney infections, reproductive tract infections, skin and soft tissue infections and bone and joint infections.
Ciprofloxacin ACS Dobfar description
Ciprofloxacin ACS Dobfar is a drug used to treat bacterial infections. It is a second generation fluoroquinolone antibacterial. It kills bacteria by interfering with the enzymes that cause DNA to rewind after being copied, which stops DNA and protein synthesis.
Ciprofloxacin ACS Dobfar is marketed worldwide with over three hundred different brand names. In the United States, Canada and the UK, it is marketed as Ciloxan, Cipro, Ciprofloxacin ACS Dobfar, Cipro XL Ciproxin and, most recently, Proquin. In Mexico it is available over the counter and marketed under the names Ciproflox or Ciprofloxacino. In Ecuador it is available and marketed under the name Cidrax. In Nigeria it is sold as Ciprotab while in Bangladesh it is marketed as Tablets and Microcapsules for Suspension by numerous companies, one of which is by Edruc Limited as Cipron. Additionally, Ciprofloxacin ACS Dobfar is available as a generic drug under a variety of different brand names and is also available for limited use in veterinary medicine.
Ciprofloxacin ACS Dobfar was first patented in 1983 by Bayer A.G. and subsequently approved by the United States Food and Drug Administration (FDA) in 1987.Ciprofloxacin ACS Dobfar has 12 F.D.A.-approved human uses and other veterinary uses, but it is often used for non-approved uses (off-label).
Ciprofloxacin ACS Dobfar interacts with other drugs, herbal and natural supplements, and thyroid medications.
Active ingredient matches for Ciprofloxacin ACS Dobfar:
Ciprofloxacin in United States.
- DailyMed. "CIPROFLOXACIN; DEXAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailymed/se... (accessed September 18, 2017).
- Wikipedia. "ciprofloxacin: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Ciprofloxa... (accessed September 18, 2017).
- PubChem. "ciprofloxacin". https://pubchem.ncbi.nlm.nih.gov/compoun... (accessed September 18, 2017).
- FDA Orange Book. "CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE: The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).". https://www.fda.gov/Drugs/InformationOnD... (accessed September 18, 2017).
ReviewsThe results of a survey conducted on ndrugs.com for Ciprofloxacin ACS Dobfar are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ciprofloxacin ACS Dobfar. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet